Comparison of Immunohistochemical and Fluorescence In Situ Hybridization Assessment for HER-2/neu Status in Taiwanese Breast Cancer Patients

• Egile Nagusiak: Shou-Jen Kuo (Egilea), Boris Bao-Tyan Wang (Egilea), Cheng-Shyong Chang (Egilea), Tze-Ho Chen (Egilea), Kun-Tu Yeh (Egilea), Dong-Jay Lee (Egilea), Pao-Lun Yin (Egilea), Ming Chen (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2007-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Objective: Accurate diagnostic assessment of human epidermal growth factor receptor-2 (HER-2) is essential and a prerequisite for appropriate application of the humanized anti-HER-2 monoclonal antibody trastuzumab (Herceptin) to the treatment of patients with breast cancer. Immunohistochemistry (IHC...